Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...

On 14 July 2025, the World Health Organization (WHO) issued new guidelines recommending twice-yearly injectable lenacapavir as an additional pre-exposure prophylaxis (PrEP) option for HIV prevention.

After a year of US funding cuts across global public health, including South Africa’s hard-hit HIV programmes, new realities ...

Opinion: "While the obstacles we face may be significant, Lenacapavir represents a monumental breakthrough in the fight against HIV/AIDS, one we can not afford to squander," write Dr. Kelly Gebo and ...

Health experts warn new HIV preventive jab does not protect against other STIs, pregnancyHealth experts are welcoming the registration of a twice-yearly injection to prevent HIV, while warning that ...

For the past three years, Buhle Sikade, 22, has been using an injection that gives her almost foolproof protection against ...

HIV/AIDS activists heralded the approval of a new twice-yearly pre-exposure prophylaxis (PrEP) medication last year, but these celebrations were tempered by insurers’ reluctance to cover its ...

GILD readies Q4 results as HIV drugs Biktarvy and Descovy drive growth, while Yeztugo uptake and cell therapy headwinds shape ...

The BRILLIANT 011, a first-in-human clinical trial, was officially launched at the Desmond Tutu HIV Foundation (DTHF) ...